Bio 242 Unit 3 Lecture 2 PP
... of the myocardium before contraction 2. Contractility: force of contraction of the ventricular ...
... of the myocardium before contraction 2. Contractility: force of contraction of the ventricular ...
Chest Pain and the BLS Provider
... • Left ventricle fails to pump forward • Blood backs up into pulmonary circulation • Characterized by: ...
... • Left ventricle fails to pump forward • Blood backs up into pulmonary circulation • Characterized by: ...
Cardiac devices in the Golden Cardiac devices in the Golden Years
... HF Scores and Palliative Care “Although these scores may be useful for defining a population for a clinical t i l th i applicability trial…their li bilit in ...
... HF Scores and Palliative Care “Although these scores may be useful for defining a population for a clinical t i l th i applicability trial…their li bilit in ...
Cardiac Exam Study Guide Page 1
... Women often present with a “triad” of symptoms, including indigestion or abdominal fullness, chronic fatigue despite adequate rest, and inability to catch one’s breath. Dyspnea that is associated with activity is referred to as dyspnea on exertion. It is usually an early symptom of heart failure ...
... Women often present with a “triad” of symptoms, including indigestion or abdominal fullness, chronic fatigue despite adequate rest, and inability to catch one’s breath. Dyspnea that is associated with activity is referred to as dyspnea on exertion. It is usually an early symptom of heart failure ...
Assessment of Cardiac Function * Am I that Different?
... • Right heart failure • Left heart failure HFREF (reduced EF) – 20% of TOF LV systolic dysfunction (Ghai 2002) – Systolic dysfunction in TOF predictor of mortality (Broberg 2011) ...
... • Right heart failure • Left heart failure HFREF (reduced EF) – 20% of TOF LV systolic dysfunction (Ghai 2002) – Systolic dysfunction in TOF predictor of mortality (Broberg 2011) ...
The Cardiac Cycle
... forcing blood through the pulmonary artery to the lungs and through the aorta to the rest of the body (0.3s) • Atrial diastole is where the atria relax. Blood will enter the atria from the large veins (0.7s) • Ventricular diastole is where the ventricles relax, and start to fill with blood from the ...
... forcing blood through the pulmonary artery to the lungs and through the aorta to the rest of the body (0.3s) • Atrial diastole is where the atria relax. Blood will enter the atria from the large veins (0.7s) • Ventricular diastole is where the ventricles relax, and start to fill with blood from the ...
Cardiology Update 2016
... with coronary disease, valvular heart disease, hypertension, cardiac arrhythmia, atrial fibrillation, and heart failure. Learning Objectives: This educational event is tailored to meet the following objectives and at the conclusion of this activity, the participants should be able to: • Describe t ...
... with coronary disease, valvular heart disease, hypertension, cardiac arrhythmia, atrial fibrillation, and heart failure. Learning Objectives: This educational event is tailored to meet the following objectives and at the conclusion of this activity, the participants should be able to: • Describe t ...
Hormones hold hope in heart disease
... “We know from existing experience that in certain subgroups of heart disease these hormones are powerful indicators of the severity of heart disease and the patient’s risk of deterioration. What we don’t know is how well we can apply those measurements across a very broad group. By coupling hormone ...
... “We know from existing experience that in certain subgroups of heart disease these hormones are powerful indicators of the severity of heart disease and the patient’s risk of deterioration. What we don’t know is how well we can apply those measurements across a very broad group. By coupling hormone ...
General Medical Officer (GMO) Manual: Clinical Section
... A gradually increasing P-R interval until a P wave fails to conduct. ...
... A gradually increasing P-R interval until a P wave fails to conduct. ...
Grade 11 Biology Worksheet -2 ( Circulatory system) a)Give one
... 1) SA node is called the pacemaker of heart. 2) The atrial systole normally precedes the ventricular systole. 3) Ventricle relaxes as a closed chamber in the early phase of its diastole. 4) You can palpate the pulse on an artery in each heart beat. 5) There is no mixing of oxygenated and deoxygenate ...
... 1) SA node is called the pacemaker of heart. 2) The atrial systole normally precedes the ventricular systole. 3) Ventricle relaxes as a closed chamber in the early phase of its diastole. 4) You can palpate the pulse on an artery in each heart beat. 5) There is no mixing of oxygenated and deoxygenate ...
Arrhythmias - The Brookside Associates
... A gradually increasing P-R interval until a P wave fails to conduct. ...
... A gradually increasing P-R interval until a P wave fails to conduct. ...
ECG and the Heart*s Internal Conduction System
... contraction & explain why each is important to cardiac function. ...
... contraction & explain why each is important to cardiac function. ...
ECG and the Heart’s Internal Conduction System
... contraction & explain why each is important to cardiac function. ...
... contraction & explain why each is important to cardiac function. ...
Heart Failure-
... Reasonable to use spironolactone to treat patients with HFpEF resembling those in the America’s enrolled in TOPCAT ...
... Reasonable to use spironolactone to treat patients with HFpEF resembling those in the America’s enrolled in TOPCAT ...
LO2 – Ionic currents that generate cardiac action potentials
... LO1. Contrast the typical action potential in a ventricular muscle and a pacemaker cell. LO2. Explain how ionic currents contribute to the five phases of the cardiac action potential. Apply this information to explain differences in shapes of the action potentials of different cardiac cells. LO3. Ex ...
... LO1. Contrast the typical action potential in a ventricular muscle and a pacemaker cell. LO2. Explain how ionic currents contribute to the five phases of the cardiac action potential. Apply this information to explain differences in shapes of the action potentials of different cardiac cells. LO3. Ex ...
Group 2 etiologyCHF
... Generally, heart failure (HF) is a clinical syndrome that occurs in patients who have an abnormality in cardiac structure or function due to either inherited or acquired causes (Mann, 2008). These abnormalities lead to cardiac dysfunction which results in inadequate cardiac and systemic perfusion (B ...
... Generally, heart failure (HF) is a clinical syndrome that occurs in patients who have an abnormality in cardiac structure or function due to either inherited or acquired causes (Mann, 2008). These abnormalities lead to cardiac dysfunction which results in inadequate cardiac and systemic perfusion (B ...
Advances in EP Cardiology - For Medical Professionals
... ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art medical therapy with either rate control or rhythm control drugs for reducing total mortality (primary endpoint) and decreasing the composite endpoint of total mortality, disabling stroke, seriou ...
... ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art medical therapy with either rate control or rhythm control drugs for reducing total mortality (primary endpoint) and decreasing the composite endpoint of total mortality, disabling stroke, seriou ...
Chronic Heart Failure Clinical Guideline No. 5 NICE – July 2003
... Introduce in a ‘start low, go slow’ manner, assessing HR, BP and clinical status after dose titration Withdrawal of beta-blockers has been shown to: increase risk of worsening heart failure increased risk of early death ...
... Introduce in a ‘start low, go slow’ manner, assessing HR, BP and clinical status after dose titration Withdrawal of beta-blockers has been shown to: increase risk of worsening heart failure increased risk of early death ...
Council on Clinical Cardiology Laennec Clinician/Educator Lecture
... Council on Clinical Cardiology Laennec Clinician/Educator Lecture This lecture was established in 1970 by the Laennec Society, a section of the Council on Clinical Cardiology, but was not presented consistently until 1978. The major aim of the Society was to promote the importance of bedside cardiol ...
... Council on Clinical Cardiology Laennec Clinician/Educator Lecture This lecture was established in 1970 by the Laennec Society, a section of the Council on Clinical Cardiology, but was not presented consistently until 1978. The major aim of the Society was to promote the importance of bedside cardiol ...
The use of a CircuLite micro-pump for congenitally corrected
... progressive decline in systemic ventricular function and the development of severe pulmonary hypertension. Despite maximal tolerated medical therapy, his condition deteriorated rapidly in March 2011 when he presented with NYHA class IV symptoms, at which time the pacemaker was upgraded to a CRT devi ...
... progressive decline in systemic ventricular function and the development of severe pulmonary hypertension. Despite maximal tolerated medical therapy, his condition deteriorated rapidly in March 2011 when he presented with NYHA class IV symptoms, at which time the pacemaker was upgraded to a CRT devi ...
Cardiovascular System
... Another characteristic is the intercalated disks; these are specialized cell junctions – they work to increase contact between the cells. This also serve to allow the cardiac muscle contract in waves to “massage” the blood out of the heart. ...
... Another characteristic is the intercalated disks; these are specialized cell junctions – they work to increase contact between the cells. This also serve to allow the cardiac muscle contract in waves to “massage” the blood out of the heart. ...
Impact of Cardiac Contractility Modulation on Left Ventricular Global
... development and testing of a host of new device-based therapies (1). One more recent and potentially broadly applicable treatment under investigation is cardiac contractility modulation (CCM) electrical signals (2,3). CCM signals are relatively high-voltage electrical impulses applied to the myocard ...
... development and testing of a host of new device-based therapies (1). One more recent and potentially broadly applicable treatment under investigation is cardiac contractility modulation (CCM) electrical signals (2,3). CCM signals are relatively high-voltage electrical impulses applied to the myocard ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.